Key Highlights
- Mumbai-based Sun Pharmaceutical Industries delivered a formal, all-cash $12 billion acquisition proposal for Organon (OGN)
- Shares of OGN skyrocketed 41% to reach $8.25 during Friday trading, following Thursday’s 18% climb to $6.91
- The Indian drugmaker wrapped up more than three months of comprehensive due diligence and is securing financing through JPMorgan and MUFG
- The transaction, if finalized, would represent the biggest international M&A deal ever executed by an Indian pharmaceutical firm
- Shares of Sun Pharmaceutical declined 3% on Mumbai exchanges amid the acquisition reports
Organon’s shares experienced an extraordinary two-day rally. The women’s health-focused pharmaceutical company based in New Jersey saw its stock price climb 41% Friday morning, reaching $8.25 per share. This surge followed Thursday’s impressive 18% increase, triggered by news that Sun Pharmaceutical Industries had presented a formal $12 billion acquisition proposal.
According to India’s Economic Times, which broke the story, the pharmaceutical giant headquartered in Mumbai has progressed past the preliminary investigation phase and delivered a binding, cash-only offer. Sun Pharma’s pursuit of this acquisition has spanned over three months.
With Organon’s market capitalization currently hovering around $1.8 billion, the proposed $12 billion purchase price represents a significant premium above its present market value.
Major financial powerhouses are backing the transaction’s financing structure. Global banking institutions including JPMorgan and Japan’s MUFG are collaborating with Sun Pharma to arrange the necessary funding.
Organon’s Corporate History
Organon emerged as an independent entity following its 2021 separation from Merck. The company specializes in women’s reproductive healthcare, including contraception and fertility treatments, while maintaining additional product lines in dermatology, neurology, and cardiovascular therapeutics.
The organization has navigated challenging times recently. This past October, Chief Executive Officer Kevin Ali departed following an internal board inquiry that uncovered what company officials characterized as inappropriate sales tactics employed to artificially boost quarterly financial performance.
Sun Pharma’s pursuit of Organon isn’t breaking news. Earlier this year in January, the Economic Times disclosed that Sun Pharma had submitted a preliminary, non-binding cash proposal and was gearing up to begin its due diligence process. Friday’s developments represent significant advancement from that initial phase.
Implications for Sun Pharmaceutical
Should the transaction close, it would establish a new benchmark as the most substantial international acquisition in the history of India’s pharmaceutical industry — a milestone achievement for the sector.
Sun Pharmaceutical’s shares experienced downward pressure following the announcement, sliding 3% on Mumbai markets Friday. Such negative market reactions are typical when acquiring companies unveil large-scale, debt-financed transactions.
Both Organon and Sun Pharmaceutical declined to provide statements in response to media inquiries regarding the reported offer.
Prior to this week’s dramatic movement, OGN shares had been languishing at suppressed price levels. The consecutive gains of 18% followed by 41% mark a remarkable reversal in investor confidence surrounding the stock.
As of Friday morning trading, Sun Pharma has reportedly entered the concluding phases of its bid process, with financial backing being secured in conjunction with the binding acquisition proposal.
